Floatz logo

Irinotecan

Acinar Cell Adenocarcinoma of the Pancreas

Artios Pharma LtdSmall moleculePhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Acinar Cell Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
Eloxatin
Yale University
Phase 2BBB
FLUOROURACILUM
Yale University
Phase 2BBB
Metformin
Case Comprehensive Cancer Center
Phase 2BB
Bryostatin 1
National Cancer Institute (NCI)
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Alliance for Clinical Trials in Oncology
Phase 2/3B

View all 34 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →